Stock 603983 GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guangdong Marubi Biotechnology Co., Ltd.

Equities

603983

CNE100003M51

Personal Products

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
28.44 CNY -2.13% Intraday chart for Guangdong Marubi Biotechnology Co., Ltd. -1.25% +12.54%
26/04 Guangdong Marubi Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Guangdong Marubi Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 24,072 20,936 12,806 13,545 10,133 11,404 - -
Enterprise Value (EV) 1 24,072 19,373 12,005 12,730 9,309 10,549 10,529 10,501
P/E ratio 46.8 x 45 x 51.4 x 78.5 x 38.9 x 30.1 x 24 x 19.9 x
Yield 0.65% 0.67% 0.6% 0.74% 2.06% 1.04% 1.27% 2.4%
Capitalization / Revenue 13.4 x 12 x 7.17 x 7.82 x 4.55 x 3.9 x 3.19 x 2.7 x
EV / Revenue 13.4 x 11.1 x 6.72 x 7.35 x 4.18 x 3.6 x 2.94 x 2.49 x
EV / EBITDA 37.8 x 32.6 x 38.4 x 54.2 x 27.6 x 22.5 x 17.7 x 14.7 x
EV / FCF - -50.1 x -96.3 x -204 x 111 x 55.7 x 27.5 x 22.1 x
FCF Yield - -2% -1.04% -0.49% 0.9% 1.8% 3.64% 4.52%
Price to Book 9.02 x 7.03 x 4.15 x 4.25 x 3.03 x 3.17 x 2.96 x 2.81 x
Nbr of stocks (in thousands) 4,01,000 4,01,000 4,01,820 4,01,445 4,01,000 4,01,000 - -
Reference price 2 60.03 52.21 31.87 33.74 25.27 28.44 28.44 28.44
Announcement Date 21/04/20 23/04/21 29/04/22 28/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,801 1,745 1,787 1,732 2,226 2,927 3,576 4,217
EBITDA 1 637.6 593.9 312.2 234.7 337.3 468.2 593.5 715.4
EBIT 1 612.6 572.5 299 207.3 319.3 466 600 729.7
Operating Margin 34.02% 32.81% 16.73% 11.97% 14.35% 15.92% 16.78% 17.3%
Earnings before Tax (EBT) 1 614 567.4 309.6 206.6 317.1 447.2 562.7 672.2
Net income 1 514.9 464.4 247.9 174.2 259.4 375.5 470.4 564.9
Net margin 28.59% 26.61% 13.87% 10.06% 11.66% 12.83% 13.15% 13.4%
EPS 2 1.284 1.160 0.6200 0.4300 0.6500 0.9448 1.184 1.427
Free Cash Flow 1 - -386.6 -124.6 -62.45 83.98 189.5 382.8 474.6
FCF margin - -22.15% -6.97% -3.61% 3.77% 6.47% 10.71% 11.25%
FCF Conversion (EBITDA) - - - - 24.9% 40.47% 64.5% 66.33%
FCF Conversion (Net income) - - - - 32.37% 50.47% 81.4% 84%
Dividend per Share 2 0.3900 0.3500 0.1900 0.2500 0.5200 0.2966 0.3599 0.6834
Announcement Date 21/04/20 23/04/21 29/04/22 28/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 S1 2023 Q3 2023 Q4 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 649.3 - 434.5 817.2 326.5 588 - - 477 689.2 753.4 616.8 846.2 - -
EBITDA - - - - - - - - - - - - - - -
EBIT 140.1 - 58.48 137.7 10.14 59.46 - - - 128.2 - - - - -
Operating Margin 21.57% - 13.46% 16.85% 3.11% 10.11% - - - 18.6% - - - - -
Earnings before Tax (EBT) 1 140.4 - 58.38 - 9.62 59.33 - - 27.61 126.3 114 93.32 98.4 - -
Net income 1 105.9 - 51.59 - 2.941 54.17 - 130.7 43.14 85.59 93.26 76.35 75.98 - -
Net margin 16.31% - 11.87% - 0.9% 9.21% - - 9.04% 12.42% 12.38% 12.38% 8.98% - -
EPS 2 0.2700 - 0.1300 - 0.0100 0.1300 - 0.3300 0.1000 0.2200 0.2326 0.1904 0.1895 - -
Dividend per Share 2 - - - - - - - - - - 0.2707 - - - 0.3182
Announcement Date 29/04/22 26/05/22 26/08/22 26/08/22 28/10/22 28/04/23 25/05/23 25/08/23 30/10/23 26/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 1,563 801 814 824 855 875 903
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -387 -125 -62.5 84 190 383 475
ROE (net income / shareholders' equity) 26.3% 16.5% 8.15% 5.56% 7.94% 10.6% 12.6% 14.4%
ROA (Net income/ Total Assets) 18.5% 12.8% 6.56% 4.44% 6.07% 7.91% 9.1% 9.99%
Assets 1 2,777 3,616 3,778 3,926 4,274 4,749 5,172 5,655
Book Value Per Share 2 6.660 7.430 7.680 7.940 8.350 8.970 9.610 10.10
Cash Flow per Share 2 1.160 0.9000 -0.0200 0.1200 0.8400 1.100 1.540 1.560
Capex 1 6.4 749 117 111 254 170 191 215
Capex / Sales 0.36% 42.92% 6.55% 6.4% 11.41% 5.82% 5.33% 5.11%
Announcement Date 21/04/20 23/04/21 29/04/22 28/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Guangdong Marubi Biotechnology Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
28.44 CNY
Average target price
33.43 CNY
Spread / Average Target
+17.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Cosmetics & Perfumes

1st Jan change Capi.
GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD. Stock Guangdong Marubi Biotechnology Co., Ltd.
+12.54% 160.38Cr
L'ORÉAL Stock L'Oréal
-6.17% 25TCr
GALDERMA GROUP AG Stock Galderma Group AG
0.00% 2.03TCr
SHISEIDO COMPANY, LIMITED Stock Shiseido Company, Limited
+13.52% 1.2TCr
COTY INC. Stock Coty Inc.
-20.17% 871.02Cr
AMOREPACIFIC CORPORATION Stock Amorepacific Corporation
+21.38% 781.58Cr
PROYA COSMETICS CO.,LTD. Stock Proya Cosmetics Co.,Ltd.
+13.29% 618.97Cr
NATURA &CO HOLDING S.A. Stock Natura &Co Holding S.A.
-7.16% 386.59Cr
KOSÉ CORPORATION Stock KOSÉ Corporation
+0.43% 379.76Cr
INTER PARFUMS, INC. Stock Inter Parfums, Inc.
-18.69% 373.27Cr
Cosmetics & Perfumes
  1. Stock Market
  2. Equities
  3. 603983 Stock
  4. Financials Guangdong Marubi Biotechnology Co., Ltd.